Extrait

The analyses described in this document are being conducted to generate estimates of the effect of mepolizumab on exacerbations requiring hospitalisation/ED visits and hospitalisation alone which are observed at relatively low frequencies in individual studies. Exacerbations requiring hospitalization/ED visits are serious for patients, but are difficult to study in a single randomised controlled clinical trial as they occur relatively infrequently. The meta-analysis will also investigate the relationship between efficacy endpoints and blood eosinophils providing further information on the relationship between baseline blood eosinophils thresholds and the effects of treatment with mepolizumab.

Critère d'inclusion

• Asthma

Liens

• gsk